Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | ABL1 | P00519 | 2/20 | 0.45 |
| ▸ | BCR | P11274 | 2/20 | 0.45 |
| ▸ | BRD4 | O60885 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.36 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3723254 | 0.87 | CYP2C19 (0.48) | L3MBTL1ABL1BCRPKMHTT | |
| SCHEMBL1356064 | 0.87 | L3MBTL1 (0.51) | L3MBTL1ABL1BCRBRD4CA1 | |
| SCHEMBL30509477 | 0.87 | L3MBTL1 (0.51) | L3MBTL1BRD4CA1CA2PKM | |
| SCHEMBL16052697 | 0.87 | L3MBTL1 (0.51) | L3MBTL1BRD4CA1CA2PKM | |
| SCHEMBL1566001 | 0.86 | L3MBTL1 (0.50) | L3MBTL1ABL1BCRBRD4CA1 | |
| SCHEMBL1565879 | 0.85 | L3MBTL1 (0.49) | L3MBTL1ABL1BCRBRD4CA1 | |
| SCHEMBL29946541 | 0.85 | L3MBTL1 (0.49) | L3MBTL1ABL1BCRBRD4CA1 | |
| SCHEMBL1748728 | 0.85 | L3MBTL1 (0.49) | L3MBTL1BRD4CA1CA2PKM | |
| SCHEMBL1718205 | 0.85 | L3MBTL1 (0.49) | L3MBTL1ABL1BCRBRD4CA1 | |
| SCHEMBL1933799 | 0.82 | L3MBTL1 (0.47) | L3MBTL1BRD4CA1CA2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220372034-A1 | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS | ACLARIS THERAPEUTICS, INC. | 2022-11-24 | — | — | US | disclosed |
| US-11420966-B2 | Substituted pyrrolopyridines as JAK inhibitors | ACLARIS THERAPEUTICS, INC. | 2022-08-23 | — | — | US | disclosed |
| US-20220235043-A1 | SUBSTITUTED SULFONAMIDE PYRROLOPYRIDINES AS JAK INHIBITORS | ACLARIS THERAPEUTICS, INC. | 2022-07-28 | — | — | US | disclosed |
| CN-113727975-A | Substituted pyrrolopyridines as JAK inhibitors | 阿克拉瑞斯治疗股份有限公司 | 2021-11-30 | — | — | CN | disclosed |
| US-20200347053-A1 | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS | ACLARIS THERAPEUTICS, INC. | 2020-11-05 | — | — | US | disclosed |
| WO-2020223728-A1 | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS | ACLARIS THERAPEUTICS, INC. (US) | 2020-11-05 | — | — | WO | disclosed |
| US-20200071326-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS INC (US) | 2020-03-05 | — | — | US | disclosed |
| WO-2018191587-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS, INC. (US) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071326-A1 | TAM KINASE INHIBITORS | PIK3CA, MAP3K1, MAP3K5 | L3MBTL1 2882/4885ABL1 34/4885BCR 1122/4885 |
| US-20220235043-A1 | SUBSTITUTED SULFONAMIDE PYRROLOPYRIDINES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | L3MBTL1 4809/4885ABL1 143/4885BCR 1398/4885 |
| US-20200347053-A1 | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | L3MBTL1 4310/4885ABL1 228/4885BCR 2843/4885 |
| US-20220372034-A1 | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | L3MBTL1 4310/4885ABL1 228/4885BCR 2843/4885 |
| US-11420966-B2 | Substituted pyrrolopyridines as JAK inhibitors | JAK1, JAK3, JAK2 | L3MBTL1 4310/4885ABL1 228/4885BCR 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.